Paydas Semra, Zorludemir Suzan, Baslamisli Fikri, Tuncer Ilhan
Department of Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey.
Leuk Lymphoma. 2002 Jan;43(1):139-43. doi: 10.1080/10428190210203.
Vascular endothelial growth factor (VEGF) plays an important role in angiogenesis. Although the role and importance of angiogenic factors such as VEGF have been established in various solid tumors, this has not been widely evaluated in hemopoietic neoplasias. In this trial, VEGF was studied in plasmacytoma and VEGF expression was compared with histopathologic grade. Forty-seven samples have taken from cases with plasmacytoma (Pm) (33 bones and 14 soft tissue plasmacytomas) were used as study material. Pm was the initial presentation in all cases, and bone marrow (BM) involvement was detected in 19 cases with systemic evaluation. Twenty-seven of the cases were male (age range was between 19 and 81 years). Histopathologically 27 cases had mature and 20 cases had immature morphology. Immunohistochemical analysis was used to detect VEGF expression and this was scored according to the percentage of the VEGF stained cells. VEGF expression was detected in 32 cases and in eight cases this expression was strong. In 11 cases expression was moderate and 13 cases showed mild expression. When we compared VEGF expression with pathologic grade, 17 of 20 immature samples showed VEGF expression while 15 of 27 mature samples showed VEGF expression. There was a statistically significant association between immature morphology and VEGF expression (p < 0.0264). Additionally all the samples, except one, with strong VEGF expression showed immature morphology. In conclusion two thirds of the cases with Pm showed VEGF expression and this was associated with immature morphology. Increased expression of VEGF was seen in plasmacytomas, and additional studies are needed to determine whether this translates to increased microvasculature or increased risk of progression to myeloma.
血管内皮生长因子（VEGF）在血管生成中起重要作用。尽管诸如VEGF等血管生成因子的作用和重要性已在各种实体瘤中得到证实，但在造血系统肿瘤中尚未得到广泛评估。在本试验中，对浆细胞瘤中的VEGF进行了研究，并将VEGF表达与组织病理学分级进行了比较。从47例浆细胞瘤（Pm）病例（33例骨浆细胞瘤和14例软组织浆细胞瘤）中获取样本作为研究材料。所有病例均以Pm为首发表现，经系统评估，19例检测到骨髓（BM）受累。27例为男性（年龄范围在19至81岁之间）。组织病理学检查显示，27例形态成熟，20例形态不成熟。采用免疫组织化学分析检测VEGF表达，并根据VEGF染色细胞的百分比进行评分。32例检测到VEGF表达，其中8例表达强，11例表达中等，13例表达弱。当我们将VEGF表达与病理分级进行比较时，20例不成熟样本中有17例显示VEGF表达，而27例成熟样本中有15例显示VEGF表达。不成熟形态与VEGF表达之间存在统计学显著关联（p < 0.0264）。此外，除1例样本外，所有VEGF表达强的样本均显示不成熟形态。总之，三分之二的Pm病例显示VEGF表达，且这与不成熟形态相关。浆细胞瘤中可见VEGF表达增加，需要进一步研究以确定这是否转化为微血管增加或进展为骨髓瘤的风险增加。
